A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 33
- Population
- ALL · 61 Years
- Duration
- 2012-05-01 to 2017-04-26
- Intervention
- sodium chloride solution 0.9%; temsirolimus
- Comparator
- sodium chloride solution 0.9%
- Outcomes measured
- median Event Free Survival (EFS) — participants will be followed for one year after start of study treatment; event free survival probability — participants will be followed for one year after start of study treatment; median Event Free Survival (EFS) of AML patients with different cytogenetic and molecular risk groups — participants wi…; rate of early response after the first induction cycle in the temsirolimus and the control group — participants will be…; rate of early response of AML patients with different cytogenetic and molecular risk groups — participants will be foll…; Complete Remission (CR) rate in the temsirolimus and the control group — participants will be followed for one year aft…; CR rate of AML patients with different cytogenetic and molecular risk groups — participants will be followed for one ye…; Relapse Free Survival (RFS) of AML patients in the temsirolimus and the control group — participants will be followed f…; Relapse Free Survival (RFS) of AML patients with different cytogenetic and molecular risk groups — participants will be…; Overall Survival (OS) of all AML patients in the temsirolimus and the control group — participants will be followed for…; Overall Survival (OS) of AML patients with different cytogenetic and molecular risk groups — participants will be follo…; rate of molecular remissions in the temsirolimus and the control group — participants will be followed for one year aft…; Number of adverse events in the temsirolimus and the control group — participants will be followed for one year after s…; rate of molecular relapse after molecular remission of all AML patients in the temsirolimus and the control group after…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.